share_log

Reviewing Protagenic Therapeutics (OTCMKTS:PTIX) & OLO (NYSE:OLO)

Reviewing Protagenic Therapeutics (OTCMKTS:PTIX) & OLO (NYSE:OLO)

普羅塔基因治療公司(OTCMKTS:PTIX)和OLO(紐約證券交易所市場代碼:OLO)綜述
Defense World ·  2022/08/02 01:41

OLO (NYSE:OLO – Get Rating) and Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

OLO(NYSE:OLO-GET Rating)和Protag Treateutics(OTCMKTS:PTIX-GET Rating)都是小盤計算機和科技公司,但哪一項是更好的投資?我們將根據這兩家公司的股息、估值、收益、分析師建議、機構所有權、盈利能力和風險等方面的實力進行比較。

Analyst Recommendations

分析師建議

This is a breakdown of current ratings and price targets for OLO and Protagenic Therapeutics, as reported by MarketBeat.com.

據MarketBeat.com報道,這是OLO和普羅吉治療公司目前的評級和目標價的細目。

Get
到達
OLO
日誌
alerts:
警報:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OLO 0 0 4 0 3.00
Protagenic Therapeutics 0 0 1 0 3.00
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
日誌 0 0 4 0 3.00
孕激素治療學 0 0 1 0 3.00

OLO currently has a consensus price target of $27.60, suggesting a potential upside of 150.91%. Protagenic Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 566.67%. Given Protagenic Therapeutics' higher probable upside, analysts clearly believe Protagenic Therapeutics is more favorable than OLO.

Olo目前的普遍目標價為27.60美元,暗示潛在上漲150.91%。普羅吉治療公司的共識目標價為4.00美元,這意味着潛在的上漲566.67%。鑑於普羅吉治療公司更有可能上行,分析人士顯然認為普羅塔吉治療公司比OLO更有利。

Profitability

盈利能力

This table compares OLO and Protagenic Therapeutics' net margins, return on equity and return on assets.
該表比較了OLO和Protag Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins Return on Equity Return on Assets
OLO -17.52% -3.09% -2.81%
Protagenic Therapeutics N/A -46.99% -41.99%
淨利潤率 股本回報率 資產回報率
日誌 -17.52% -3.09% -2.81%
孕激素治療學 不適用 -46.99% -41.99%

Institutional & Insider Ownership

機構與內部人持股

75.3% of OLO shares are held by institutional investors. Comparatively, 11.1% of Protagenic Therapeutics shares are held by institutional investors. 45.0% of Protagenic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

75.3%的OLO股份由機構投資者持有。相比之下,Protag Treateutics 11.1%的股份由機構投資者持有。普羅泰根治療公司45.0%的股份由公司內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一隻股票有望實現長期增長。

Volatility & Risk

波動性與風險

OLO has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

OLO的貝塔係數為1.24,這意味着其股價的波動性比標準普爾500指數高24%。相比之下,普羅吉治療公司的貝塔係數為-0.12,這意味着其股價的波動性比標準普爾500指數低112%。

Valuation & Earnings

估值與收益

This table compares OLO and Protagenic Therapeutics' revenue, earnings per share (EPS) and valuation.

該表比較了OLO和普羅吉治療公司的收入、每股收益(EPS)和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OLO $149.37 million 11.71 -$42.27 million ($0.18) -61.11
Protagenic Therapeutics N/A N/A -$4.52 million N/A N/A
總收入 價格/銷售額比 淨收入 每股收益 市盈率
日誌 1.4937億美元 11.71 -4,227萬元 ($0.18) -61.11
孕激素治療學 不適用 不適用 -452萬美元 不適用 不適用

Protagenic Therapeutics has lower revenue, but higher earnings than OLO.

普羅吉治療公司的收入低於OLO,但收益高於OLO。

Summary

摘要

OLO beats Protagenic Therapeutics on 6 of the 10 factors compared between the two stocks.

在兩隻股票之間的10個因素中,OLO在6個因素上擊敗了普羅吉治療公司。

About OLO

關於OLO

(Get Rating)

(獲取評級)

Olo Inc. provides software-as-a-service platform for multi-location restaurants in the United States. The company's platform enables on-demand commerce operations, which cover digital ordering and delivery through online and mobile ordering modules. Its modules include Order Management, an on-demand digital commerce and channel management solutions that enables consumers to order directly from and pay restaurants via mobile, web, kiosk, voice, and other digital channels; and Delivery Enablement, a fulfillment network, as well as a network aggregator and channel management solution, which enables restaurants to offer, manage, and expand direct delivery, as well as allows restaurants to control and syndicate menu, pricing, location data, and availability, while directly integrating and optimizing orders from third-parties into the restaurants' point-of-sale and systems. The company also provides Customer Engagement solution, a suite of restaurant-centric marketing and sentiment solutions that enables restaurants to collect, analyze, and act on guest data; Front-of-House solution, which enables restaurants to streamline the queue orders from multiple sales channels; and Payment solution, a payment platform that offers fraud prevention that results in enhanced authorization rates for valid transactions. The company was formerly known as Mobo Systems, Inc. and changed its name to Olo Inc. in January 2020. Olo Inc. was incorporated in 2005 and is headquartered in New York, New York.

Olo Inc.為美國的多家餐廳提供軟件即服務平臺。該公司的平臺支持按需商務運營,其中包括數字訂購和通過在線和移動訂購模塊交付。它的模塊包括Order Management,一種按需數字商務和渠道管理解決方案,使消費者能夠通過移動、網絡、售貨亭、語音和其他數字渠道直接從餐廳訂購併支付;Delivery Enablement,一種履行網絡,以及網絡聚合器和渠道管理解決方案,使餐廳能夠提供、管理和擴大直接送貨,並允許餐廳控制和辛迪加菜單、定價、位置數據和可用性,同時將來自第三方的訂單直接集成和優化到餐廳的銷售點和系統中。該公司還提供客户參與解決方案,這是一套以餐廳為中心的營銷和情緒解決方案,使餐廳能夠收集、分析客人數據並採取行動;前置解決方案,使餐廳能夠簡化來自多個銷售渠道的排隊訂單;以及支付解決方案,提供防欺詐功能,從而提高有效交易的授權率。該公司前身為Mobo Systems,Inc.,於2020年1月更名為Olo Inc.。Olo Inc.成立於2005年,總部設在紐約。

About Protagenic Therapeutics

關於前列腺素治療學

(Get Rating)

(獲取評級)

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

前列基因治療公司是一家生物製藥公司,致力於發現和開發治療與壓力相關的神經精神和情緒障礙的療法。它的先導化合物是PT00114,這是Teneurin羧基末端相關肽的合成形式,Teneurin羧基末端相關肽是一種內源性大腦信號肽,可以抑制過度活躍的應激反應。該公司總部設在紐約,紐約州。

Receive News & Ratings for OLO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLO and related companies with MarketBeat.com's FREE daily email newsletter.

接收OLO日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對OLO和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論